STAA Staar Surgical Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: STAA

Price (delayed)

$63.62

Market cap

$3.07B

P/E Ratio

78.54

Dividend/share

N/A

EPS

$0.81

Enterprise value

$3.01B

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are ...

Highlights
STAA's P/E is 72% below its 5-year quarterly average of 280.8 and 19% below its last 4 quarters average of 96.4
Staar Surgical's net income has soared by 58% YoY and by 2.5% from the previous quarter
STAA's quick ratio is down by 10% QoQ but it is up by 6% YoY
Staar Surgical's debt has increased by 3.7% from the previous quarter but it has decreased by 3.2% YoY
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.staar.com
Peers: COO ATRI IRIX ABT

Key stats

What are the main financial stats of STAA
Market
Shares outstanding
48.24M
Market cap
$3.07B
Enterprise value
$3.01B
Valuations
Price to earnings (P/E)
78.54
Price to book (P/B)
9.23
Price to sales (P/S)
10.73
EV/EBIT
69.91
EV/EBITDA
63.29
EV/Sales
10.6
Earnings
Revenue
$284.39M
EBIT
$43.1M
EBITDA
$47.61M
Free cash flow
$17.61M
Per share
EPS
$0.81
Free cash flow per share
$0.37
Book value per share
$6.89
Revenue per share
$5.93
TBVPS
$8.61
Balance sheet
Total assets
$414.9M
Total liabilities
$82.71M
Debt
$31.04M
Equity
$332.19M
Working capital
$260.01M
Liquidity
Debt to equity
0.09
Current ratio
6.03
Quick ratio
5.3
Net debt/EBITDA
-1.16
Margins
EBITDA margin
16.7%
Gross margin
78.5%
Net margin
13.6%
Operating margin
15.4%
Efficiency
Return on assets
10.1%
Return on equity
12.6%
Return on invested capital
20.1%
Return on capital employed
11.9%
Return on sales
15.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

STAA stock price

How has the Staar Surgical stock price performed over time
Intraday
0.22%
1 week
6.1%
1 month
10.97%
1 year
-15.12%
YTD
31.07%
QTD
31.07%

Financial performance

How have Staar Surgical's revenue and profit performed over time
Revenue
$284.39M
Gross profit
$223.38M
Operating income
$43.8M
Net income
$38.76M
Gross margin
78.5%
Net margin
13.6%
Staar Surgical's net income has soared by 58% YoY and by 2.5% from the previous quarter
STAA's operating income is up by 31% year-on-year but it is down by 13% since the previous quarter
Staar Surgical's net margin has increased by 28% YoY
The gross profit has grown by 25% year-on-year and by 2.2% since the previous quarter

Growth

What is Staar Surgical's growth rate over time

Valuation

What is Staar Surgical stock price valuation
P/E
78.54
P/B
9.23
P/S
10.73
EV/EBIT
69.91
EV/EBITDA
63.29
EV/Sales
10.6
STAA's P/E is 72% below its 5-year quarterly average of 280.8 and 19% below its last 4 quarters average of 96.4
Staar Surgical's EPS has surged by 56% YoY and by 3.8% QoQ
STAA's price to book (P/B) is 37% lower than its 5-year quarterly average of 14.7 and 15% lower than its last 4 quarters average of 10.8
Staar Surgical's equity has increased by 28% YoY and by 3.8% QoQ
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 15.4 and 13% less than its last 4 quarters average of 12.3
The revenue has grown by 23% YoY

Efficiency

How efficient is Staar Surgical business performance
The ROIC has decreased by 37% YoY and by 25% from the previous quarter
Staar Surgical's return on assets has increased by 26% YoY
The ROE has grown by 24% YoY but it has contracted by 3.8% from the previous quarter
Staar Surgical's return on sales has increased by 12% YoY but it has decreased by 7% QoQ

Dividends

What is STAA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STAA.

Financial health

How did Staar Surgical financials performed over time
The total assets is up by 20% year-on-year and by 5% since the previous quarter
Staar Surgical's total liabilities has increased by 11% from the previous quarter but it has decreased by 5% YoY
Staar Surgical's debt is 91% less than its equity
Staar Surgical's equity has increased by 28% YoY and by 3.8% QoQ
The company's debt to equity fell by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.